Learn about Ionis Pharmaceuticals' innovative RNA-targeted therapy and their potential for significant revenue growth. Read ...

A novel study from Korea uncovers the process of synthesis and pivotal role of the transfer RNA-derived fragment, ...

Mipomersen — which is being developed by Genzyme and Isis Pharmaceuticals — is a synthetic antisense oligonucleotide that targets messenger RNA encoding apolipoprotein B100 (APOB100).

See how small bits of non-coding RNA target mRNA for destruction and ... to various diseases by injecting manufactured dsRNA or antisense siRNA strands into cells (Whalley, 2006).

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis ... competition – notably Novartis' small interfering RNA (siRNA) therapy Leqvio (inclisiran), which only ...

I am interested in deciphering the functional role of noncoding RNA (ncRNA) in gene regulation network governing forest tree growth and development. One significant class of such ncRNA is natural ...

RES-010 represents a first-in-class antisense oligonucleotide targeting miR-22, a non-coding RNA that plays a pivotal role in the molecular pathways underlying obesity. This innovative approach ...

Transfer RNA-derived fragments (tRFs) are small molecules present in most organisms. tRHs or tRNA halves are generated when certain tRFs are split at specific sites by enzymes. Although ...

Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering ...